Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Which patients with moderate hypoxemia benefit from long-term oxygen therapy? Ways forward

Ekström, Magnus LU orcid and Ringbaek, Thomas (2018) In International Journal of COPD 13. p.231-235
Abstract

Long-term oxygen therapy (LTOT) improves prognosis in patients with COPD and chronic severe hypoxemia. The efficacy in moderate hypoxemia (tension of arterial oxygen; on air, 7.4−8.0 kPa) was questioned by a recent large trial. We reviewed the evidence to date (five randomized trials; 1,191 participants, all with COPD). Based on the current evidence, the survival time may be improved in patients with moderate hypoxemia with secondary polycythemia or right-sided heart failure, but not in the absence of these signs. Clinically, LTOT is not indicated in moderate hypoxemia except in the few patients with polycythemia or signs of right-sided heart failure, which may reflect more chronic and severe hypoxemia.

Please use this url to cite or link to this publication:
author
and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
COPD, Hypoxemia, Oxygen therapy, Survival
in
International Journal of COPD
volume
13
pages
5 pages
publisher
Dove Medical Press Ltd.
external identifiers
  • scopus:85040923967
  • pmid:29386891
ISSN
1176-9106
DOI
10.2147/COPD.S148673
language
English
LU publication?
yes
id
b03790b9-5bad-4164-b475-8aa470e077b7
date added to LUP
2018-02-23 18:43:02
date last changed
2024-04-01 01:42:40
@article{b03790b9-5bad-4164-b475-8aa470e077b7,
  abstract     = {{<p>Long-term oxygen therapy (LTOT) improves prognosis in patients with COPD and chronic severe hypoxemia. The efficacy in moderate hypoxemia (tension of arterial oxygen; on air, 7.4−8.0 kPa) was questioned by a recent large trial. We reviewed the evidence to date (five randomized trials; 1,191 participants, all with COPD). Based on the current evidence, the survival time may be improved in patients with moderate hypoxemia with secondary polycythemia or right-sided heart failure, but not in the absence of these signs. Clinically, LTOT is not indicated in moderate hypoxemia except in the few patients with polycythemia or signs of right-sided heart failure, which may reflect more chronic and severe hypoxemia.</p>}},
  author       = {{Ekström, Magnus and Ringbaek, Thomas}},
  issn         = {{1176-9106}},
  keywords     = {{COPD; Hypoxemia; Oxygen therapy; Survival}},
  language     = {{eng}},
  month        = {{01}},
  pages        = {{231--235}},
  publisher    = {{Dove Medical Press Ltd.}},
  series       = {{International Journal of COPD}},
  title        = {{Which patients with moderate hypoxemia benefit from long-term oxygen therapy? Ways forward}},
  url          = {{http://dx.doi.org/10.2147/COPD.S148673}},
  doi          = {{10.2147/COPD.S148673}},
  volume       = {{13}},
  year         = {{2018}},
}